C34
Conditions
Interventions
Group 1: Patients with suspected or histologically confirmed NSCLC who are clinically indicated for FDG PET/CT.
Sponsors
Universitätsklinikum Tübingen, Nuklearmedizin
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: • Patients with clinical suspicion or histologically confirmed NSCLC ((non small cell lung carcinoma) • Justifying clinical indication for a [18F]FDG-PET investigation • Patients who tolerate 1 h measurement time in the PET/CT scanner • Age =18 years • Written consent of the patient
Exclusion criteria
Exclusion criteria: • pregnant and nursing women • Patients with claustrophobia • Patients with back pain problems / pain that may not tolerate a one-hour measurement period • Exclusion criteria according to German StrlSchV • Limited ability to consent of the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Collection of dynamic PET parameters (Ki, DV, K1 and Vb) from the primary tumor, lymph node regions and distant metastases of NSCLC patients and their correlation with histopathological findings ("gold standard") of the same regions (feasibility study). Histopathological analyzes are performed on biopsies or surgical material collected as part of the routine care of patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Differentiation of inflammatory and tumor-associated tissue changes by means of suitable dynamic PET parameters, • Identification of malignant lymph nodes using dynamic PET parameters, • Establishment of the workflow for a dynamic wb-PET/CT in NSCLC patients. (Endpoint of the study: PET/CT datasets and immunhistol. analyses of tissue probes (taken as part of standard of care) are available) | — |
Countries
Germany
Contacts
Public ContactMatthias Weissinger
Universitätsklinikum Tübingen, Nuklearmedizin
Outcome results
None listed